Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2014 |
| Start Date: | May 2009 |
| End Date: | May 2013 |
| Contact: | Stephen Schuster, MD |
| Email: | PennCancerTrials@emergingmed.com |
| Phone: | 855-216-0098 |
A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography,
may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma
cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and
computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell
lymphoma.
may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma
cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and
computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell
lymphoma.
OBJECTIVES:
I. Assess the feasibility of detection and quantification of differences in the temporal and
spatial distribution of FDG uptake between lesions of HL and DLBCL.
OUTLINE:
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography
scans 60 and 180 minutes after FDG administration.
After completion of study, patients are followed for 24 hours.
I. Assess the feasibility of detection and quantification of differences in the temporal and
spatial distribution of FDG uptake between lesions of HL and DLBCL.
OUTLINE:
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography
scans 60 and 180 minutes after FDG administration.
After completion of study, patients are followed for 24 hours.
Inclusion Criteria:
- Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with
measurable disease by any imaging technique or physical examination.
Exclusion Criteria:
- Pregnant or nursing,
- Uncontrolled diabetes mellitus,
- Active infection,
- Inability to give informed consent or to comply with all study procedures,
- Subjects may be excluded at the discretion of the principal investigator or study
team members.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
